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SUMMARY 
 
Background: To compare the inter-practice and inter-regional variability in laboratory test requests by general 
practitioners in Spain, through the measure of appropriateness indicators. 
Methods: A call for data was posted on the Redconlab website. We obtained production statistics for 2010 from 
laboratories in 37 different hospitals from diverse Spanish regions. The following appropriateness indicators were 
calculated: test requests per 1000 inhabitants, ratios of related tests requests and index of variability. The results 
obtained in the laboratories in the region of authors were compared to the rest of the participating laboratories in 
order to establish whether there were regional differences in the test requesting patterns. 
Results: The rate of request of the tests ranged from 31.5 per 1000 inhabitants for vitamin B12 to 372.6 per 1000 
inhabitants for glucose. The index of variability ranged from 1.53 for glucose and triglycerides to 7.4 for alkaline 
phosphatase. Regarding the ratios of related test requests, the variability index ranged from 1.24 for folic acid/vi-
tamin B12 to 26.38 for lactate dehydrogenase/alanine transaminase. The most frequently ordered tests were the 
ones with less variability, except for uric acid and urinalysis. No significant differences were identified between 
the results of the laboratories in the region of authors and the rest, except for urinalysis (p < 0.001), folic acid/vita-
min B12 (p = 0.030), and transferrin/ferritin (p = 0.018). 
Conclusions: A considerable variability exists in laboratory test ordering patterns by general practitioners across 
Spanish regions. Local habits must have been decisive as shown by the regional differences in the results of indica-
tors of some tests. The study results bring out the need to accomplish interventions to improve appropriate use of 
laboratory tests. 
(Clin. Lab. 2014;60:xx-xx. DOI: 10.7754/Clin.Lab.2013.130101) 
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INTRODUCTION 
 
The use of laboratory tests has increased over the last 
years [1], and Spain is not an exception [2]. Several 
studies have suggested that inappropriate test requests 
are a primary reason for such an increase [3]. The rate 
of inappropriate test requests ranges from 4.5% to 95%, 
as shown by studies of medical records using implicit 
and explicit criteria [4]. Reasons for excessive tests or-
dered by physicians include defensive behavior and fear 
or uncertainty, lack of experience, the use of protocols 
and guidelines, “routine” clinical practice, inadequate 
educational feedback, and clinician's unawareness about 
the cost of examinations [5]. Inappropriate testing 
causes unnecessary patient discomfort, entails the risk 
of generating false/positive results, leads to overloading 
of the diagnostic services, wastes valuable healthcare 
resources, and is associated with other inefficiencies in 
healthcare delivery, undermining the quality of health 
services [6]. According to some authors [7], there is no 
clear correlation between the number of tests and the 
quality of patient care. 
The “initial selection” of tests by clinicians could take 
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Table 1. Laboratory organizational data. 
 
Patient served 8130334 inhabitants % 
Geographical distribution 
20 Valencian laboratories 54.0% 
17 Laboratories of other region 46.0% 
Institution type 
Public 34 92.0% 
Public with private 
management 
3 8.0% 
Population served - number of primary health areas 
40000 - 100000 5 13.5% 
100000 - 200000 11 29.7% 
200000 - 300000 14 37.8% 
> 300000 7 18.9% 
Institution location 
Urban 78.0% 
Rural 22.0% 
No. of beds, mean (CI 95%) 431.45 (321.02-541.88) 
 
CI - Confidence interval of the mean. 
 
 
 
 
into consideration the geological conditions, for exam-
ple iodine deficiency in limestone regions that may lead 
to the increased frequency of specific tests. The topo-
graphical conditions may influence requests from rural 
or urban/industrial regions. 
Inappropriate tests could be defined as “those that could 
reasonably be avoided at no significant detriment of pa-
tient care”. Inappropriateness for over or under request-
ing could occur. The latter is more difficult to detect [8]. 
Identifying inadequacies in the use of diagnostic tests 
should be one of the duties of pathologists. For this pur-
pose, the first step would be to examine the use of tests 
in our laboratory and compare it with others to examine 
overspending and to optimize the use of testing in order 
to reduce costs and increase the quality of the request 
process [9,10]. 
The aim of our study was to compare the inter-practice 
and inter-regional variability in laboratory tests request-
ed by general practitioners (GPs) in Spain, using the 
measurement of appropriateness indicators. 
 
 
MATERIALS AND METHODS 
 
Data collection 
A call for data was posted on the Redconlab website. 
Spanish laboratories willing to participate in the study 
were invited to fill out an enrollment form and submit 
their results on-line. We obtained production statistics 
(number of tests requested by GPs) for 2010 from 37 
laboratories at different hospitals from diverse regions 
across Spain. 28 clinical chemistry tests were examined 
in a cross-sectional study. These 28 parameters were se-
lected based on previous experience in this field [11]. 
Every patient seen in any primary care center (PCC) of 
any of these 37 institutions, regardless of the reason for 
consultation, gender or age, was included in the study. 
Each participating laboratory was required to be able to 
obtain patient data from local databases and to provide 
organizational data (i.e., population served, public/pri-
vate management, number of beds, location). 
 
Data processing 
After collecting data, 2 types of appropriateness indica-
tors were calculated by a single coordination center: test 
requests per 1000 inhabitants or ratios of related tests 
requests. In order to explore the inter-practice variabili-
ty, a third indicator, the “index of variability”, was cal-
culated as follows: top decile divided by bottom decile. 
With these data, a frequency histogram and a box plot 
for each of the indicators was drawn, and a pre-pre-ana-
lytical quality control report was prepared. This report 
was sent to each participating laboratory indicating their 
individual results compared to those of the others. Each 
report had 28 sheets, each including a single indicator: 
test ordered per 1000 inhabitants for 16 tests and ratios 
for 12 related test requests (Figure 1). 
The indicators obtained in the laboratories in the region 
of authors (the Valencian Community, 20 laboratories; 
4150793 patients) were compared to the pooled results 
of the remaining ones (17 laboratories; 3979541 pa-
tients) in order to establish whether there were regional 
differences in the requesting patterns. In addition, the 
indicators were compared by location of hospitals (rural 
vs. urban). 
 
Statistical methods 
The statistical treatment of the previously calculated da-
ta included: the distribution, the mean, 95% confidence 
level for the mean, standard deviation, median, and in-   
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Table 2. Mean, median, range and variability index (Percentil90/Percentil10) of every indicator result. 
 
 Mean Median Range Variability index* 
Tests requesting per 1000 inhabitants 
Glucose 372.6 366.4 227.9 - 486.3 1.5 
Triglycerides 342.4 333.2 226.7 - 456.2 1.5 
Cholesterol 357.1 353.3 226.3 - 470.9 1.5 
Creatinine 351.7 344.5 184.1 - 481.9 1.6 
Alanine transaminase (ALT) 332 329 179.0 - 490.1 1.7 
Cholesterol. HDL 275 279 131.5 - 407.0 1.8 
Glycosylated hemoglobin 85 88.8 53.0 - 134.5 2.0 
Thyrotropin (TSH) 174.4 178.6 108.1 - 285.4 2.1 
Prostate-specific antigen (PSA) 51.1 51 19.1 - 85.2 2.1 
Uric acid 298.5 302.1 106.4 - 434.0 2.2 
Ferritin 130.9 127 74.7 - 202.7 2.2 
C-Reactive protein (CRP) 60.6 53.1 21.2 - 239.8 3.5 
Urinalysis 196.7 211.2 18.2 - 345.2 3.8 
Vitamin B 12 31.5 27.8 4.0 - 88.0 6.4 
Calcium (Ca) 88.2 80.3 14.9 - 291.4 7.0 
Alkaline phosphatase (ALP) 139.1 125.5 9.3 - 306.5 7.4 
Related test requesting ratio 
Folic acid/Vitamin B 12 0.9 1.0 0.5 - 1.2 1.2 
Gamma-Glutamyltransferase (GGT)/ALT 0.8 0.9 0.2 - 1.0 2.1 
Iron/Ferritin 1.0 1.0 0.3 - 1.9 2.4 
Aspartate transaminase (AST)/ALT 0.8 0.9 0.1 - 1.0 2.8 
Phosphate/Ca 0.7 0.7 0.1 - 1.0 3.3 
Total bilirubin (tBILT)/ALP 1.2 1.0 0.3 - 6.4 4.3 
Urea/Creatinine 0.6 0.6 0.0 - 1.1 5.6 
Thyroxine (FT4)/TSH 0.4 0.3 0.1 - 1.0 6.1 
Free PSA (FPSA)/PSA 0.1 0.1 0.0 - 0.5 9.4 
Transferrin/Ferritin 0.4 0.3 0.0 - 1.0 12.3 
Direct bilirubin/tBIL 0.1 0.1 0.0 - 0.9 23.2 
Lactate dehydrogenase (LDH)/ALT 0.1 0.1 0.0 - 0.7 26.4 
 
* - P90/P10. 
 
 
 
 
terquartile range. 
The analysis of the distribution was conducted by way 
of the Kolmogorov-Smirnov test. A t-test analysis was 
conducted to examine if there were regional differences 
or laboratory locations in the results of the indicators 
that followed a normal distribution, and a Kruskal-Wal-
lis test analysis to show whether the indicators followed 
a non-Gaussian distribution. A two-sided p ≤ 0.05 rule 
was utilized as the criterion for rejecting the null hypo-
thesis of no difference. 
 
RESULTS 
 
Table 1 displays a summary of the organizational data 
of the different laboratories that participated in the 
study. In all laboratories tests could be either requested 
in profiles or individually. 
As shown in Table 2, the rate of request of the tests 
ranged from 31.5 per 1000 inhabitants for vitamin B12 
to 372.6 per 1000 inhabitants for glucose. The index of 
variability ranged from 1.5 for glucose and triglycerides 
to 7.4 for alkaline phosphatase (ALP). Regarding the ra-   
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Table 3. Comparison between Spanish regions: Valencia Community, other Spanish regions and p-value of every indicator re-
sult. 
 
 Valencia Community Other Spanish Regions  
Tests requesting per 1000 inhabitants 
 Mean ± SD Mean ± SD p 
Alanine transaminase (ALT) 329.4 ± 70.2 335.2 ± 62.6 0.794 
Cholesterol 348.2 ± 57.1 367.6 ± 57.6 0.311 
Cholesterol, HDL 263.6 ± 58.0 288.4 ± 68.1 0.238 
Creatinine 346.6 ± 65.9 357.7 ± 64.0 0.607 
Ferritin 127.1 ± 33.4 135.4 ± 34.6 0.480 
Glucose 369.5 ± 59.2 376.2 ± 66.0 0.748 
Glycosylated hemoglobin 87.7 ± 18.8 81.9 ± 26.5 0.439 
Prostate-specific antigen (PSA) 50.6 ± 12.2 51.6 ± 16.6 0.829 
Thyrotropin (TSH) 166.5 ± 39.5 183.6 ± 43.5 0.218 
Triglycerides 338.3 ± 54.2 347.1 ± 54.0 0.622 
Uric acid 291.8 ± 71.0 306.2 ± 79.0 0.562 
Urinalysis 159.1 ± 74.1 241.0 ± 49.0 < 0.001 * 
 Median - (IQR) Median - (IQR) p 
Alkaline phosphatase (ALP) 112.3 - (64.1 - 179.9) 162.7 - (117.3 - 188.9) 0.055 
Calcium (Ca) 62.7 - (37.7 - 107.5) 94.5 - (58.3 - 110.8) 0.161 
C-Reactive protein (CRP) 57.6 - (44.1 - 73.3) 51.8 - (29.5 - 63.3) 0.247 
Vitamin B 12 22.9 - (16.2 - 35.9) 32.1 - (14.58 - 53.2) 0.487 
Related test requesting ratio 
 Mean ± SD Mean ± SD p 
Aspartate transaminase (AST)/ALT 0.75 ± 0.29 0.81 ± 0.28 0.494 
Folic acid/Vitamin B12 0.97 ± 0.09 0.88 ± 0.13 0.030 * 
Gamma-Glutamyltransferase (GGT)/ALT 0.74 ± 0.23 0.84 ± 0.15 0.131 
Iron/Ferritin 0.96 ± 0.27 1.10 ± 0.40 0.251 
Phosphate/Ca 0.66 ± 0.20 0.65 ± 0.27 0.862 
 Median - (IQR) Median - (IQR) p 
Direct bilirubin/BILT 0.06 - (0.03 - 0.15) 0.05 - (0.03 - 0.07) 0.211 
Free PSA (FPSA)/PSA 0.15 - (0.10 - 0.20) 0.12 - (0.10 - 0.14) 0.120 
Lactate dehydrogenase (LDH)/ALT 0.05 - (0.02 - 0.16) 0.11 - (0.04 - 0.31) 0.120 
Thyroxine (FT4)/TSH 0.31 - (0.24 - 0.45) 0.31 - (0.21 - 0.49) 0.903 
Total bilirubin (BILT)/ALP 0.99 - (0.75 - 1.27) 1.05 - (0.97 - 1.21) 0.334 
Transferrin/Ferritin 0.24 - (0.17 - 0.51) 0.51 - (0.25 - 0.87) 0.022 * 
Urea/Creatinine 0.58 - (0.29 - 0.91) 0.73 - (0.44 - 0.96) 0.315 
 
* - p < 0.05. 
 
 
 
 
tios of related test requests, the variability between lab-
oratories was even greater. The variability index for 
these indicators ranged from 1.2 for folic acid/vitamin 
B12 to 26.4 for lactate dehydrogenase (LDH)/alanine 
transaminase (ALT). 
The most frequently requested tests were the ones with  
less variability, except for uric acid and urinalysis. Ta-
ble 2 shows the descriptive analysis of the different in-
dicators of laboratory tests requested according to their 
variability index. 
Table 3 compares the appropriateness indicators obtain-
ed at the laboratories in the region of authors (the Va-      
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Table 4. Comparison between hospital location: Rural, urban and p-value of every indicator result. 
 
 Rural Urban  
Tests requesting per 1000 inhabitants 
 Mean ± SD Mean ± SD p 
Alanine transaminase (ALT) 342.0 ± 84.5 329.3 ± 61.4 0.635 
Cholesterol 359.2 ± 68.4 356.5 ± 55.4 0.907 
Cholesterol, HDL 267.4 ± 68.1 277.1 ± 62.9 0.706 
Creatinine 362.6 ± 74.2 348.7 ± 62.5 0.598 
Ferritin 124.0 ± 44.2 133.0 ± 30.7 0.517 
Glucose 382.6 ± 67.9 369.9 ± 60.8 0.613 
Glycosylated hemoglobin 92.3 ± 29.5 83.0 ± 20.4 0.307 
Prostate-specific antigen (PSA) 59.6 ± 16.7 48.7 ± 12.8 0.054 
Thyrotropin (TSH) 184.9 ± 63.4 171.5 ± 34.5 0.426 
Triglycerides 344.5 ± 66.0 341.8 ± 51.0 0.901 
Uric acid 331.5 ± 68.8 289.3 ± 74.0 0.157 
Urinalysis 196.7 ± 87.6 196.7 ± 73.4 0.999 
 Median - (IQR) Median - (IQR) p 
Alkaline phosphatase (ALP) 69.1 - (37.7 - 131.4) 141.8 (102.6 - 188.5) 0.658 
Calcium (Ca) 94.7 - (26.5 - 176.9) 80.4 - (48.6 - 108.5) 0.150 
C-Reactive protein (CRP) 53.0 - (36.0 - 78.0) 53.1 - (37.3 - 67.3) 0.971 
Vitamin B 12 19.6 - (16.5 - 37.5) 29.3 - (16.2 - 13.5) 0.666 
Related test requesting ratio 
 Mean ± SD Mean ± SD p 
Aspartate transaminase (AST)/ALT 0.87 ± 0.26 0.76 ± 0.28 0.325 
Folic acid/Vitamin B12 0.99 ± 0.10 0.91 ± 0.12 0.108 
Gamma-Glutamyltransferase (GGT)/ALT 0.79 ± 0.19 0.78 ± 0.21 0.955 
Iron/Ferritin 0.87 ± 0.28 1.07 ± 0.34 0.154 
Phosphate/Ca 0.50 ± 0.19 0.70 ± 0.22 0.024 * 
 Median - (IQR) Median - (IQR) p 
Direct bilirubin/BILT 0.03 - (0.03 - 0.15) 0.05 - (0.03 - 0.08) 0.795 
Free PSA (FPSA)/PSA 0.11 - (0.08 - 0.26) 0.14 - (0.11 - 0.18) 0.796 
Lactate dehydrogenase (LDH)/ALT 0.09 - (0.03 - 0.19) 0.06 - (0.03 - 0.22) 0.971 
Thyroxine (FT4)/TSH 0.21 -  (0.13 - 0.30) 0.34 - (0.24 - 0.49) 0.012 * 
Total bilirubin (BILT)/ALP 1.17 - (1.05 - 1.36) 1.00 - (0.88 - 1.16) 0.105 
Transferrin/Ferritin 0.31 - (0.16 - 0.63) 0.34 - (0.2 - 0.7) 0.556 
Urea/Creatinine 0.67 - (0.57 - 0.93) 0.64 - (0.31 - 0.94) 0.507 
 
* - p < 0.05. 
 
 
 
 
lencian Community) and the ones obtained for the rest, 
in alphabetical order. 
No significant differences were noticed between our re-
sults and those of other Spanish regions, except for uri-
nalysis (p < 0.001), folic acid/vitamin B12 (p = 0.030) 
and transferrin/ferritin (p = 0.018) ratios. 
Table 4 compares appropriateness indicators obtained in  
the rural location and those of the urban laboratories. 
No significant differences were obtained between test 
ordering patterns by general practitioners in rural or ur-
ban locations, except for phosphate (P)/calcium (Ca) 
and free thyroxine (FT4)/thyrotropin (TSH). 
 
 
M. SALINAS et al. 
Clin. Lab. 3+4/2014 6 
 
 
 
 
 
 
Figure 1. One of the report sheets sent to every laboratory that participated in the study. 
 
 
 
 
 
DISCUSSION 
 
This is the first study that evaluates the use of laborato-
ry tests in primary care in different health care regions 
in Spain. It shows a high variability in every indicator 
studied. In general, the less the test is requested the 
more variability is observed. 
The observed variability is very difficult to explain 
based only on differences in the characteristics of the 
patients. Local habits must have been decisive as shown 
by the regional differences in the results of indicators of 
some tests. There was not a systematic over or under re-
questing in any region compared to the others. In the in-
ter-regional comparison, urinalysis was considerably 
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over-requested when compared with the Valencian 
Community; however, folate and transferrin were un-
der-requested. 
Current guidelines recommend an active request of tri-
glycerides, glucose, creatinine, glycosylated hemoglo-
bin, ferritin, thyrotropin (TSH), and calcium [11] to de-
pict treatable diseases in an early stage. The previous 
guidelines, however, do not state which reference val-
ues should be achieved. Accordingly, the question is: to 
what levels should we stimulate demand for those tests? 
Triglycerides, cholesterol, creatinine, and glucose are 
considered routine laboratory tests for preventive health 
exams to promote healthier behaviours, and their high 
demand may be justified. On the other hand, glycosylat-
ed hemoglobin [12] and TSH are probably under re-
quested [13]. The first is the best disease marker in dia-
betic patients and its use has been extended not only to 
monitor but also to the diagnosis of the disease [14]. 
The latter is very useful to detect thyroid dysfunction, 
especially in middle aged women and older patients that 
may have very unclear symptoms [13]. 
Regarding ferritin, should it be requested in primary 
care only when microcytic anemia is diagnosed? Should 
it also be requested in subjects without anemia to inves-
tigate iron deposits? Its demand in some areas (200/ 
1000 inhabitants) seems to be too high if we consider it 
appropriate to request it only in patients with anemia 
[15]. Indeed, there are different points of view in litera-
ture with respect to which marker should be chosen in 
patients with microcytic anemia. Some authors recom-
mend ferritin as the front line marker [16], while others 
propose transferrin and transferrin saturation index. Fer-
ritin results might be biased in some cases as elevated 
levels are seen in inflammations, malignant diseases, 
and alcoholism. By analysing ferritin and transferrin to-
gether, the majority of iron-metabolism disorders can be 
explained (in conjunction with a blood smear). Howev-
er, ferritin is still considered the first marker for early 
depiction of uncomplicated iron deficiency, such as pre-
ventive health exams or during pregnancy. 
There was a high variability in the request of calcium, 
ranging from 14.9 to 291.4 per 1000 inhabitants. It sug-
gests that calcium could be under requested in some ar-
eas, which could indicate that hyperparathyroidism may 
be overlooked. The group of middle-aged women is not 
the only group for a thyroid disorder. They often suffer 
from hyperparathyroidism, which is detected either too 
late or by chance. Hyperparathyroidism has very diffuse 
symptoms and elevated serum calcium levels can un-
mask the disease. The results of this study show that the 
use of calcium should be encouraged in less demanding 
areas. 
The results of the indicators suggest that uric acid may 
be over requested [7]. This could be potentially danger-
ous since its use for screening purposes may lead to 
treatment of “asymptomatic hyperuricemia” or overload 
the rheumatology consultation. Unexpected pathologic 
values could cause unneeded repeated visits. 
Although urinalysis is not recommended as a screening  
test for reasons of cost-benefit, the study results show 
that it continues to be frequently requested in primary 
care services. This high request for urinalysis may be 
due to the noninvasive type of test that provides an 
overview of the situation of the patients. 
It is difficult to justify a request of prostate-specific an-
tigen (PSA) in primary care patients since nowadays its 
usefulness for screening purposes is controversial, even 
when requested in those older than 50 [17]. 
The behavior of the request of some tests has been mea-
sured through indicators of ratios of related test re-
quests. It is a practical way not only to measure request-
ing activity but especially to monitor changes over time. 
Values below 1 are recommended. In our study this oc-
curred for free-thyroxine/TSH, direct bilirubin/total bil-
irubin (tBIL), and free-PSA/total-PSA. There was, how-
ever, a great variability between areas. 
Serum ALT is the recommended screening test for liver 
disease, ALP is the second choice and bilirubin should 
be requested only when icterus is suspected [18].  
Such an approach would reduce aspartate transaminase 
(AST)/ALT, tBIL/ALP, LDH/ALT and gamma-glu-
tamyl transferase (GGT)/ALT ratios. In the PCC of cer-
tain health care areas the liver test profile - that can be 
requested by simply checking a box - includes more 
than one of those tests. This probably resulted in labora-
tory misuse. It is well known that even if the single tests 
are relatively cheap the results may cause an expensive 
state of "a person with an abnormal laboratory value” 
[19]. We found a wide variability in the urea/creatinine 
index, indicating that urea could be requested in excess. 
Urea is not an organ-specific test and creatinine is a bet-
ter marker of renal function. 
To summarize, the results of the indicators for uric acid, 
urianalysis, AST, and urea are possibly overused and 
glycosylated hemoglobin, TSH, and calcium seems un-
derused in most Spanish regions. 
The main limitation of the study is that the differences 
in test requesting patterns could be explained by case 
mix variations in the different PCCs, the possible vari-
ability in the patient population they attended or the use 
of different request forms or panels by the doctors. 
 
 
CONCLUSION 
 
The study results emphasize the need to accomplish in-
terventions to improve appropriate laboratory use. Inter-
departmental and inter-regional cooperation would be 
crucial to develop protocols and guidelines in order to 
optimize the use of laboratory tests, which support 
many clinical decisions [20]. 
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